Wave Life Sciences Posts 9.2% Visceral Fat Cut, 0.9% Lean Mass Gain, Eyes 2026 Phase II
Wave Life Sciences shares traded at $14.54 on Feb 25 after WVE-007’s INLIGHT trial delivered a 9.2% visceral fat reduction and a 0.9% lean mass gain. Durability showed 75%-78% silencing to Day 85 with no GI events and Phase II is planned for 2026 to test WVE-007 solo and with GLP-1s.
1. INLIGHT Trial Results
WVE-007 achieved a 9.2% placebo-adjusted reduction in visceral fat and a 0.9% gain in lean mass in the INLIGHT trial, demonstrating a muscle-sparing mechanism that differentiates it from traditional GLP-1 obesity therapies.
2. Durability and Safety Profile
Durability data showed 75%-78% Activin E silencing through Day 85 with no gastrointestinal adverse events or discontinuations, supporting the potential for a once-or-twice-yearly dosing regimen and enhanced patient adherence.
3. Phase II Program and Strategic Outlook
Wave Life Sciences plans a Phase II program in 2026 to evaluate WVE-007 as monotherapy and in combination with GLP-1 agents, with six-month follow-up data from the 240mg cohort and three-month data from the 400mg cohort due in Q1 2026, positioning the company for strategic partnerships or M&A.